These are tough drugs to create and sad that this one did not make the grade.  What is also a bit disappointing too was that this was a joint effort with Japanese Takeda Drug so not good news for them either in light of everything else Japan is dealing with.  In other cancer news of late, Amgen made a purchase of another cancer biotech company that is doing research for treating melanoma and a few other types of cancer and are also moving into a new building in Freemont, CA.  BD

Amgen to Acquire BioVex, a Privately Held Biotechnology Company in Massachusetts

Boehringer Ingelheim Buys Amgen Fremont, California Facility

An experimental treatment for lung cancer made by Amgen Inc. and Takeda Pharmaceutical Co. failed to help patients live longer in a late-stage study needed for regulatory approval.
The drug, called motesanib, didn't meet its main goal of improving survival in a study of 1,090 patients with non- squamous non-small cell lung cancer, the companies said in a statement today. Detailed results from the study will be presented at a medical meeting, the companies said.

Amgen lung cancer drug fails in late-stage study -


Post a Comment

Google Analytics Alternative